ArticleAmerican journal of translational research2026
Therapeutic efficacy of combined esmolol and carvedilol treatment for myocardial ischemia in patients with coronary heart disease.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effects of esmolol plus carvedilol in treating myocardial ischemia in coronary heart disease (CHD), with a focus on blood pressure (BP), heart rate (HR), and safety.
methodsA total of 120 patients with CHD-related myocardial ischemia admitted to our hospital between January 2022 and January 2023 were enrolled. Among them, 60 patients were treated with carvedilol monotherapy (control group), and the other 60 cases received esmolol in combination with carvedilol (research group). Therapeutic efficacy, BP, HR, premature beat counts, dynamic electrocardiogram parameters (duration and frequency of ST-segment depression), cardiac function indicators (left ventricular end-diastolic dimension [LVEDD], left ventricular posterior wall thickness [LVPWT], left ventricular septal thickness [LVST], left ventricular ejection fraction [LVEF]), and biochemical indicators (N-terminal pro-B-type natriuretic peptide [NT-proBNP], superoxide dismutase [SOD]) were assessed. Safety profiles, including nausea and vomiting, hypotension, and drowsiness, were recorded. Furthermore, factors influencing therapeutic efficacy were analyzed.
resultsCompared with the control group, patients in the research group exhibited significantly lower BP (systolic: (105.27±7.72) mmHg vs. (113.78±11.46) mmHg; diastolic: (64.98±4.81) mmHg vs. (71.35±7.76) mmHg and HR (67.90±5.63) bpm vs. (85.67±7.35) bpm). In addition, post-treatment premature beat counts (premature ventricular contraction count: (71.15±26.02) times/24 h vs. (253.67±78.62) times/24 h; premature atrial contraction count: (105.35±41.38) times/24 h vs. (279.53±59.30) times/24 h; junctional premature contraction count: (73.85±30.65) times/24 h vs. (153.58±40.07) times/24 h) were notably reduced in the research group. The duration ((22.90±3.43) min vs. (54.50±4.34) min) and frequency ((7.25±1.97) times vs. (12.47±3.33) times), of ST-segment depression were significantly decreased in the research group. Moreover, LVEDD ((42.05±4.21) mm vs. (46.48±3.98) mm), LVPWT ((9.23±2.25) mm vs. (11.18±2.59) mm), LVST ((8.72±2.48) mm vs. (10.30±2.71) mm), and NT-proBNP ((310.63±32.83) pg/mL vs. (403.87±40.51) pg/mL) were significantly reduced in the research group, whereas LVEF ((59.63±6.77)% vs. (53.73±5.04)%) and SOD ((112.72±10.12) U/mL vs. (90.60±9.85) U/mL) were significantly increased. The overall incidence of adverse events was lower in the research group. Multivariate analysis identified HR (OR=4.592, 95% CI: 1.289-16.366, P=0.019), LVEF (OR=0.290, 95% CI: 0.086-0.976, P=0.046), and NT-proBNP (OR=3.729, 95% CI: 1.124-12.371, P=0.031) as independent factors influencing therapeutic efficacy.
conclusionsEsmolol combined with carvedilol demonstrates superior efficacy and safety compared with carvedilol monotherapy in patients with myocardial ischemia secondary to CHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.